Medikamente: Forschung nach Antibiotika kommt schleppend voran

The article begins with a brief overview of the market landscape for antibacterials, reporting that large research-based pharmaceutical companies are increasingly withdrawing from antibiotic development due to poor financial rewards. The article then focuses on the progress reported by the Benchmark:

But there is also good news again: Some research companies are on the ball. 

The article then provides insight into the leaders' performances, the size of their R&D pipelines and access to essential antibiotics. It concludes with a quote from Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation:

 "It must be clear to us that antibiotic resistance is developing very quickly. However, companies are not interested in antibiotic development if it does not generate profits and there is no market potential Then there is a risk that we will also lose what little we still have. "